# HbA<sub>1c</sub> as a Marker of Glycaemic Control in Diabetes Care

Sally M Marshall
University of Newcastle upon Tyne

# What do we require of a marker of glycaemic control in diabetes care?

# The Impact of Diabetes Acute Events

Significant morbidity and mortality from:

- Hypoglycaemia
- Hyperglycaemia / ketoacidosis

#### Need for:

- Real-time, near-patient and laboratory monitoring, for diagnosis and for day-to-day treatment adjustment
- Assessment of long-term risk of acute events

# The Impact of Diabetes Long-Term Events

- Average life-expectancy reduced by 7-10 years
   premature vascular disease
- Commonest cause of blindness in Western world in people aged <65 years
- Commonest single cause of end-stage renal disease world-wide
- Commonest non-traumatic cause of amputation

### **Long-Term Monitoring**

#### Need test which:

- Relates glucose control to risk of long-term complications
- Allows estimate of risk of microvascular and macrovascular complications
- Allows setting of appropriate individual targets

→ must relate to DCCT / UKPDS HbA<sub>1c</sub>

#### **Audit and Research**

#### Research:

Compare the effectiveness of new and old treatments


#### Audit and Benchmarking

- Setting appropriate targets
- Monitoring and comparing achieved targets locally, nationally, internationally


#### Reducing the Impact of Diabetes

• Diabetes Control and Complications Trial


• UK Prospective Diabetes Study



# Severe Hypoglycaemia and HbA<sub>1c</sub>




#### Fatal and Non-Fatal Myocardial Infarction




UKPDS 35. BMJ 2000; 321: 405-12

#### Microvascular Endpoints



UKPDS 35. BMJ 2000; 321: 405-12


### **EDIC 8-year Open Follow-Up**





## HbA<sub>1c</sub> in Populations


- Relates glucose control to risk of long-term complications
- Allows estimate of risk of microvascular and macrovascular complications
- Allows setting of appropriate group targets

But is it good enough in individuals?









### But is the HbA<sub>1c</sub> Assay Reproducible?

Is HbA<sub>1c</sub> of 7.5 % the same in


Nottingham

as Newcastle

as Oxford

as Minneapolis?


# Laboratory Measurement of HbA<sub>1c</sub>



### Point of Care vs Laboratory Glucose

Mean
Difference
0.36 mmol/l
(-2.07 - 2.79)

P = 0.007




# Variation Between Blood Glucose Meters

Range	Average % Difference			
(mmol/l)	Between Meters			
	A vs B	A vs C	A vs D	A vs E
4 – 6	1.7	10.5	2.8	14.7
6 - 8	4.6	6.5	-1.4	10.3
8 - 11	2.6	6.9	4.0	8.9

Kimberly, Clin Chim Acta 2005; in press

### **Accuracy of CGMS**




- accurate
- serious errorbenign error

Kovatchev Diabetes Care 2004;27:1922

# Precision of HbA<sub>1c</sub> assay as good as near-patient blood glucose testing and has much better quality control


# Biological Variation of HbA<sub>1c</sub>

Non-diabetic distribution




Kilpatrick ES et al. Diabetes Care. 1998; 21:261-4

# Mean Plasma Glucose vs HbA<sub>1c</sub>




Rohlfing CL et al Diabetes Care 2002;25:275-8



Diabetes Care 2004;27:1259-64

### **HGI and Risk of Complications**



# HbA<sub>1c</sub> Limitations

- Haemoglobinopathies can screen for
- Anaemia
   can measure and usually correct
- Renal failure

newer assays- no interference from carbamylation

abnormal RBC turnover still a problem

## HbA<sub>1c</sub>

- Meets the requirements for a satisfactory marker for risk of complications in diabetes care:
  - Glucose
  - Non-glucose
- Most of its limitations have been/can be overcome